Induction chemotherapy was tested over the span of a decade on 500 patients with cervical cancer at medical facilities in the UK, Mexico, India, Italy, and Brazil.
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
Based on data from a randomized trial presented at ESMO, the Netherlands Cancer Institute is exploring the possibility of seeking regulatory approval for TIL therapy without pharma involvement.
Data from two Phase III studies showed at ESMO that patients with BRCA1/2 mutations and HRD are living longer with maintenance therapy with Lynparza alone and in combination with Avastin.